CN115040629A - 一种防治慢性支气管炎的中药组合物及其制备方法 - Google Patents
一种防治慢性支气管炎的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN115040629A CN115040629A CN202210903133.4A CN202210903133A CN115040629A CN 115040629 A CN115040629 A CN 115040629A CN 202210903133 A CN202210903133 A CN 202210903133A CN 115040629 A CN115040629 A CN 115040629A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- chronic bronchitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 206010006458 Bronchitis chronic Diseases 0.000 title claims abstract description 35
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 35
- 208000007451 chronic bronchitis Diseases 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000209140 Triticum Species 0.000 claims abstract description 32
- 235000021307 Triticum Nutrition 0.000 claims abstract description 32
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 241000218671 Ephedra Species 0.000 claims abstract description 16
- 241000758794 Asarum Species 0.000 claims abstract description 14
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 14
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 12
- 235000008397 ginger Nutrition 0.000 claims abstract description 12
- 239000010440 gypsum Substances 0.000 claims abstract description 12
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 238000009835 boiling Methods 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 241000234314 Zingiber Species 0.000 claims description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000010410 layer Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 3
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000012211 aluminium silicate Nutrition 0.000 claims description 3
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 3
- 229960003022 amoxicillin Drugs 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 3
- 229960001668 cefuroxime Drugs 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 3
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960004483 doxofylline Drugs 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229960003376 levofloxacin Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021317 phosphate Nutrition 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960005224 roxithromycin Drugs 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 208000037883 airway inflammation Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 210000004072 lung Anatomy 0.000 description 21
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 235000019504 cigarettes Nutrition 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 244000144725 Amygdalus communis Species 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001673966 Magnolia officinalis Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241001522129 Pinellia Species 0.000 description 4
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明涉及中医药技术领域,具体涉及一种防治慢性支气管炎的中药组合物及其制备方法,所述中药组合物是由如下所述重量份配比的原料药制成:厚朴10‑20份、麻黄8‑16份、燀苦杏仁8‑16份、清半夏8‑16份、干姜3‑9份、细辛3‑9份、五味子5‑10份、石膏15‑25份、小麦25‑35份。本发明的一种防治慢性支气管炎的中药组合物及其制备方法,可有效减轻气道炎症,实现对慢性支气管炎的防治。
Description
技术领域
本发明涉及中医药技术领域,具体涉及一种防治慢性支气管炎的中药组合物及其制备方法。
背景技术
慢性支气管炎特指支气管内壁及邻近实质部位的持续性炎症病变及其引发的肺功能进行性下降类疾病,其公认的临床诊断定义是持续2年以上且每年持续3个月以上的咳嗽、咳痰。吸烟是慢性支气管炎的重要诱因,吸入肺部的香烟烟雾中的化学成分可诱发肺部异常、过度的炎症反应,且不会因戒烟而立刻消除,导致疾病的持续存在及反复发作。随着流行病学的深入研究,生物质燃料不充分燃烧形成的烟雾、汽车尾气及部分职业(矿业、畜牧业、农业)的气体环境暴露也被证实为慢性支气管炎的诱发因素。炎症细胞在气道周边的募集是慢性支气管炎最显著的病理特征,此外还涉及气道黏液分泌量的异常增加。这些病理变化会使患者气道管腔的空间体积显著缩小,甚至出现阻塞。在疾病发展的终末期,患者肺部的气体流通会受到严重限制,呼吸功能大幅度下降,演变为慢性阻塞性肺疾病。慢性支气管炎的发生、发展涉及肺部的炎症反应及黏液的异常分泌,二者既可被环境中的刺激因素诱发,又可通过各自的病理产物来相互调节,导致疾病的不断恶化。复杂的发病机制决定了单一效应的药物只能缓解急性症状,患者为避免病情反复而需要长期用药,带来了较大的医疗经济负担。促炎因子肿瘤坏死因子-α、白介素-6通过招募炎症细胞并诱导其分泌损伤介质来造成继发性的组织损伤,在慢性支气管炎的病理学中起核心作用。此外,二者也可通过多种信号传导途径来诱导气道黏蛋白的过度分泌,导致咳痰症状及气道部位的黏液瘀滞。可以看出,能否控制气道炎症是衡量药物疗效的重要指标。慢性支气管炎虽然是现代医学体系下的病症,但诸多中医学者已经建立起了与之对应的具有中医特色的病证理论及治疗原则,为针对性治疗慢性支气管炎的中医方药的筛选提供了理论基础。复杂的发病机制决定了单一效应的药物只能缓解急性症状,患者为避免病情反复而需要长期用药,给社会带来了较大的医疗经济负担。
发明内容
鉴于此,本发明提供一种防治慢性支气管炎的中药组合物及其制备方法,可有效减轻气道炎症,实现对慢性支气管炎的防治。
为达到上述目的,本发明的技术方案如下:
本发明提供一种防治慢性支气管炎的中药组合物,所述中药组合物是由如下所述重量份配比的原料药制成:厚朴10-20份、麻黄8-16份、燀苦杏仁8-16份、清半夏8-16份、干姜 3-9份、细辛3-9份、五味子5-10份、石膏15-25份、小麦25-35份。
进一步地,所述中药组合物是由如下所述重量份配比的原料药制成:厚朴15份、麻黄 12份、燀苦杏仁12份、清半夏12份、干姜6份、细辛6份、五味子8份、石膏18份、小麦30份。
进一步地,所述中药组合物还包含有以治疗有效量存在的中药组合物与至少一种药学可接受的赋形剂的混合物。
进一步地,所述中药组合物还包含有一种常规的用于治疗慢性支气管炎的药物,该药物选自地塞米松、盐酸氨溴索、左氧氟沙星、罗红霉素、阿莫西林、头孢呋辛或多索茶碱种的任一一种。
进一步地,所述中药组合物可根据需要加入可接受的载体制备成任何药用剂型,其中,药学上可接受的载体包括但不限于:甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、红糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁。
进一步地,所述中药组合物的剂型包括颗粒、胶囊、片剂、口服液、合剂或糖浆剂中的任一一种。
本发明还提供一种中药组合物的制备方法,该方法为:
步骤1:取小麦25-35份,将小麦加水煎煮后滤过,煎煮液备用;
步骤2:取厚朴10-20份、麻黄8-16份、燀苦杏仁8-16份、清半夏8-16份、干姜3-9份、细辛3-9份、五味子5-10份、石膏15-25份,放置于上述煎煮液内浸泡并煎煮;
步骤3:将步骤2中浸泡并煎煮后的原料用纱布滤过,并干燥成干膏粉,即制得防治慢性支气管炎的中药组合物。
进一步地,所述步骤1包括有:取小麦30份,以小麦重量份为基准,剩余原料按原料药的重量份配比,随后先加75-80倍体积份水煎煮小麦,沸前用武火,沸后改用文火保持微沸状态煎煮20-30分钟,捞出小麦,煎煮液备用。
进一步地,所述步骤2包括有:用步骤1中煎煮液浸泡剩余原料25-35分钟后煎煮,沸前用武火,沸后改用文火保持微沸状态煎煮110-130分钟。
进一步地,所述步骤3中的纱布为单层或双层纱布,且所述纱布的孔径为100-300目。
综上所述,本发明具有以下技术效果:
本发明中,中药组合物包括有厚朴、麻黄、燀苦杏仁、清半夏、干姜、细辛、五味子、石膏、小麦,其中组合中的厚朴宽胸开蔽,燀苦杏仁通泄肺气,麻黄解表出邪,干姜、五味子、清半夏、细辛化痰涤饮,小麦引药入胃,其配伍合理,组方严谨,疗效确切,对于治疗慢性支气管炎具有明显的疗效,可达到标本兼治,宣肺肺平喘,镇咳祛痰的功效。
附图说明
为了更清楚地说明本发明实施例中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1为各组小鼠肺组织切片示意图:
图2为各组小鼠肺组织中肿瘤坏死因子-α、白介素-6含量图。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
以下结合具体情况说明本发明的示例性实施例:
本发明提供一种防治慢性支气管炎的中药组合物,中药组合物是由如下重量份配比的原料药制成:厚朴10-20份、麻黄8-16份、燀苦杏仁8-16份、清半夏8-16份、干姜3-9 份、细辛3-9份、五味子5-10份、石膏15-25份、小麦25-35份。
中药组合物是由如下重量份配比的原料药制成:厚朴15份、麻黄12份、燀苦杏仁12份、清半夏12份、干姜6份、细辛6份、五味子8份、石膏18份、小麦30份。
中药组合物剂型是颗粒、胶囊、片剂、口服液、合剂或糖浆剂中的任一一种。
一种防治慢性支气管炎的中药组合物的制备方法,该方法为:步骤1:取小麦25-35份,将小麦加水煎煮后滤过,煎煮液备用;步骤2:取厚朴10-20份、麻黄8-16份、燀苦杏仁8-16份、清半夏8-16份、干姜3-9份、细辛3-9份、五味子5-10份、石膏15-25份,放置于上述煎煮液内浸泡并煎煮;步骤3:将步骤2中浸泡并煎煮后的原料用纱布滤过,并干燥成干膏粉,即制得防治慢性支气管炎的中药组合物。
步骤1包括有:取小麦30份,以小麦重量份为基准,剩余原料按原料药的重量份配比,随后先加75-80倍体积份水煎煮小麦,沸前用武火,沸后改用文火保持微沸状态煎煮20-30分钟,捞出小麦,煎煮液备用。
步骤2包括有:用步骤1中煎煮液浸泡剩余原料25-35分钟后煎煮,沸前用武火,沸后改用文火保持微沸状态煎煮110-130分钟。
步骤3中的纱布为单层或双层纱布,且纱布的孔径为100-300目。
本发明还提供一种防治慢性支气管炎的中药组合物在制备防治慢性支气管炎药物中的应用,具体为:该中药组合物包含以治疗有效量存在的中药组合物与至少一种药学可接受的赋形剂的混合物,还包含:一种常规的用于治疗慢性支气管炎的药物,该药物选自地塞米松、盐酸氨溴索、左氧氟沙星、罗红霉素、阿莫西林、头孢呋辛或多索茶碱中的任一一种。
中药组合物可根据需要加入可接受的载体制备成任何药用剂型。其中,药学上可接受的载体包括但不限于:甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、红糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁。
本发明中“药学可接受的”表示化合物或组合物必须在化学上和/或毒理学上与制剂中包含的其他成分相容。“治疗有效量”表示本发明化合物治疗或预防特定疾病或症状;减弱、改善或消除特定疾病的一种或多种症状;或预防或延迟特定疾病或症状的发作的量。
本发明中,中药组合物包括有厚朴、麻黄、燀苦杏仁、清半夏、干姜、细辛、五味子、石膏、小麦,其中组合中的厚朴宽胸开蔽,燀苦杏仁通泄肺气,麻黄解表出邪,干姜、五味子、清半夏、细辛化痰涤饮,小麦引药入胃,其配伍合理,组方严谨,疗效确切,对于治疗慢性支气管炎具有明显的疗效,可达到标本兼治,宣肺肺平喘,镇咳祛痰的功效。
实施例1:称取小麦30g置锅中,加水2400mL,武火煮沸后文火微沸煎煮30min。捞出小麦后用小麦液浸泡剩余饮片(厚朴15g、麻黄12g、燀苦杏仁12g、清半夏12g、干姜6g、细辛6g、五味子8g、石膏18g)30min,武火煮沸后文火微沸煎煮120min 至煎煮液体积剩余600mL。煎煮液用双层200目纱布过滤后分取100mL至烧杯中,-80℃预冷12h后冷冻干燥(-50℃,0~5Pa),研磨、混匀即得中药组合物。
实施例2:取实施例1所述中药组合物,按适当比例加入颗粒剂辅料,按相应工艺制备成中药组合物颗粒剂。
实施例3:取实施例1所述中药组合物,按适当比例加入口服液辅料,按相应工艺制备成中药组合物口服液。
实施例4:取实施例1所述中药组合物,按适当比例加入片剂辅料,按相应工艺制备成中药组合物片剂。
实施例5:取实施例1所述中药组合物,按适当比例加入胶囊剂辅料,按相应工艺制备成中药组合胶囊剂。
以下是:实验例1中药组合物对慢性支气管炎小鼠模型的保护作用研究;
1.实验仪器与材料
1.1仪器
Sorvall Legend Micro 17型离心机(美国Thermo Fisher Scientific公司);Axio Observer 3型荧光倒置显微镜(德国卡尔蔡司股份公司);Epoch 2TC型酶联免疫检测仪 (美国Bio-Tek公司);F6/10型手持式高速匀浆机(上海净信实业发展有限公司);自制熏箱:以硬木板为材料,搭建1m×1m×1m的正六面立方体,设置顶面可开合,以锡箔纸为原料捏制4个固定点,使用透明胶带固定在四纵面中心处。
1.2材料
中药组合物;地塞米松(dexamethasone,DXMS)(批次:100129-201506,纯度:99.8%,中国食品药品检定研究院);脂多糖(lipopolysaccharide,LPS)(批次:818E035,纯度:98%以上,生物来源为Escherichia coli 055:B5,北京索莱宝科技有限公司);4%多聚甲醛组织固定液(批次:20200911,北京索莱宝科技有限公司);苏木精-伊红(hematoxylin-eosin,HE)染色试剂盒(批次:20211111,北京索莱宝科技有限公司);肿瘤坏死因子-α(批次:L210423372)、白介素-6(批次:L210413814)ELISA试剂盒,购自武汉云克隆科技股份有限公司;泰山牌香烟(焦油量:8mg,山东中烟公司)。
1.3实验动物
BALB/c小鼠48只,雄性,SPF级,体重(20±2)g,购自北京斯贝福生物技术有限公司。动物生产许可证号:SCXK(京)2016-0006,实验使用许可证号:SYXK(京)2016-0038。饲养环境的温度为(25±2)℃,相对湿度为(60±5)%,每隔12h进行明、暗环境交替变化。在实验开始前适应性喂养7d。
2.实验方法
2.1动物模型建立及给药
除空白组(8只)外,其余小鼠在第1天进行LPS气管注射。每只小鼠腹腔注射水合氯醛水溶液(5g/L)0.2~0.5mL,无明显活动后仰位固定头、四肢。于鼻尖下4cm处的颈部皮层纵向剪开一1~1.5cm的创口,再用镊子分拨皮下的肌肉、薄膜及腺体以露出气管,使用微量注射器在鼻尖下2.5~3cm处刺入约1cm,缓慢注射2g/L的LPS生理盐水溶液25μL。注射后先直立小鼠,此时可闻及明显喘息声,伴口部大幅度开合。待喘息减弱、呼吸恢复5~10min后缝合创口。第2天在自制熏箱内进行香烟烟熏。于固定点放置 4根香烟,明火灼烧烟头3~5s后立刻使用吹尘球鼓吹点火处以助燃,待可见明显、持续的着火点后封盖。每10min开盖换气以避免小鼠窒息,同时更换香烟。每组、每日烟熏2 次,每次30min,每组8只,持续14d。第16天再次按照相同操作注射LPS,第17天继续烟熏并持续14d。
第30天烟熏完成后随机分为5组,分别灌胃给予等体积溶媒(模型组)、DXMS0.09mg/kg (DXMS组)、中药组合物3.6g/kg(中药组合物高剂量组)、中药组合物1.8g/kg(中药组合物中剂量组)及中药组合物0.9g/kg(中药组合物低剂量组)。空白组给予等体积溶媒。连续给药30d,并在每次给药前按照相同方法进行香烟烟熏。使用2g/L的羧甲基纤维素钠水溶液来配置灌胃液。灌胃体积设置为0.2mL/次。
2.2肺组织匀浆液的制备
在最后一次给药后断水、断食12h,脱颈椎处死,摘取肺脏。左肺用PBS溶液(0.02mol/L, 4℃)漂洗,剪成小块并用滤纸吸附水分,称重后放入离心管。按照质量(g):体积(mL) =1:10,向离心管中先加入一半PBS溶液(0.02mol/L,4℃),在冰块中用匀浆机匀磨至无明显组织块,匀浆液转移至新离心管后使用剩余PBS溶液(0.02mol/L,4℃)润洗旧离心管并与之前的匀浆液合并。匀浆液在5000×g下离心5min,取上清液即得。
2.3肺部病理切片的制备
2.3.1石蜡切片的制备
摘取右肺,在4%多聚甲醛中固定72h后,在脱水机中依次用75%乙醇、85%乙醇、90%乙醇、95%乙醇、无水乙醇I、无水乙醇Ⅱ处理4h、2h、2h、1h、0.5h、0.5h以脱水。使用二甲苯I、Ⅱ各进行10min的透明处理后,在58℃环境中浸蜡,在包埋机中包埋成蜡块。蜡块在-20℃预处理后用切片机制成4μm切片,在40℃环境下平摊后转移至载玻片,60℃烘烤以除去水、蜡,即得。
2.3.2HE染色
将2.3.1项下的切片用二甲苯I、Ⅱ各处理20min,再用无水乙醇I、无水乙醇Ⅱ、75%乙醇、水各处理5min以复水。先用苏木精液处理5min,水洗后用分化液分化,水洗后使用返蓝液返蓝,再水洗。之后,用85%乙醇、95%乙醇各处理5min,再用伊红液处理5min。染色后的切片依次用无水乙醇I、无水乙醇Ⅱ、无水乙醇Ⅲ、二甲苯I、二甲苯Ⅱ处理5min,在中性树胶中封片,即得。
2.4检测
在显微镜下观察各组小鼠肺部病理切片。按照ELISA试剂盒中的说明书检测肺组织匀浆液中肿瘤坏死因子-α、白介素-6的含量。
2.6数据分析
数据以平均数加减标准差(x±s)的形式表示。使用SPSS 25.0进行统计学分析,采用单因素方差分析进行显著性分析,组间比较采用LSD检验。P<0.05代表差异有统计学意义。
3.结果
3.1各组小鼠肺部病理学观察
如图1所示,图1中,A:空白组;B:模型组;C:DXMS组;D:中药组合物低剂量组; E:中药组合物中剂量组;F:中药组合物高剂量组;空白组的支气管形态基本正常,气道上皮细胞排列较为整齐,管腔内无明显渗出物,间质无明显的炎症细胞浸入,周边肺泡结构基本正常。与空白组相比,模型组的支气管管腔内出现明显的炎症细胞渗入及气道上皮细胞脱落现象(黄色虚线箭头),并形成气管堵塞,周边肺泡壁也有所增厚,间质部位也出现炎症细胞浸润(黄色实线箭头)。与模型组相比,各给药组支气管部位的病理损伤得到明显改善。其中,中药组合物低剂量组、中药组合物中剂量组中虽仍有部分细支气管存在气道上皮细胞脱落及堵塞现象(黄色虚线箭头),但间质部位的炎症细胞浸润现象得到明显改善。DXMS组、中药组合物高剂量组的支气管形态基本正常,气道上皮细胞脱落现象得到明显改善,间质部位未见明显的炎症细胞浸润。
3.2请参考图2,图中各组小鼠肺组织中肿瘤坏死因子-α、白介素-6含量(n=8,pg/mL),注:a:与空白组比较,差异有统计学意义(P<0.01);b:与模型组比较,差异有统计学意义(P<0.01);
ELISA检测结果,与空白组相比,模型组小鼠肺组织中的肿瘤坏死因子-α、白介素-6 含量升高,差异有统计学意义(P<0.01)。与模型组小鼠比较,DXMS组、中药组合物中剂量组及中药组合物高剂量组小鼠肺组织中的肿瘤坏死因子-α、白介素-6含量降低,差异有统计学意义(P<0.01),中药组合物低剂量组小鼠虽然表现出下降趋势,但差异无统计学意义(P>0.05)。
4.结论
中药组合物对小鼠支气管部位的炎症损伤表现出良好的保护作用,可以有效地减轻炎症细胞浸润,改善上皮细胞脱落,避免气道部位的阻塞。ELISA检测结果表明厚朴麻黄汤可显著下调肺部的肿瘤坏死因子-α、白介素-6含量,表明其具有明确的抗炎作用。慢性支气管炎患者的气道分泌物、血液常具有较高水平的肿瘤坏死因子-α、白介素-6,两种细胞因子的量化数据是评价疾病严重程度及恶化风险的重要参考指标。在CB相关的药理实验中,支气管部位炎症损伤的缓解常伴随着肿瘤坏死因子-α、白介素-6含量的显著下降,表明通过抑制这两种细胞因子在肺部的过度分泌对于控制疾病发展具有重要意义。
最后,还需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。在没有更多限制的情况下,由语句“包括一个……”限定的要素,并不排除在包括所述要素的过程、方法、物品或者设备中还存在另外的相同要素。
以上对本发明所提供的具体实施方式进行了详细介绍,本文中应用了具体个例对本发明的原理及实施方式进行了阐述,以上实施例的说明只是用于帮助理解本发明的方法及其核心思想;同时,对于本领域的一般技术人员,依据本发明的思想,在具体实施方式及应用范围上均会有改变之处,综上所述,本说明书内容不应理解为对本发明的限制。
Claims (10)
1.一种防治慢性支气管炎的中药组合物,其特征在于,所述中药组合物是由如下所述重量份配比的原料药制成:厚朴10-20份、麻黄8-16份、燀苦杏仁8-16份、清半夏8-16份、干姜3-9份、细辛3-9份、五味子5-10份、石膏15-25份、小麦25-35份。
2.根据权利要求1所述的一种防治慢性支气管炎的中药组合物,其特征在于,所述中药组合物是由如下所述重量份配比的原料药制成:厚朴15份、麻黄12份、燀苦杏仁12份、清半夏12份、干姜6份、细辛6份、五味子8份、石膏18份、小麦30份。
3.根据权利要求1所述的一种防治慢性支气管炎的中药组合物,其特征在于,所述中药组合物还包含有以治疗有效量存在的中药组合物与至少一种药学可接受的赋形剂的混合物。
4.根据权利要求1所述的一种防治慢性支气管炎的中药组合物,其特征在于,所述中药组合物还包含有一种常规的用于治疗慢性支气管炎的药物,该药物选自地塞米松、盐酸氨溴索、左氧氟沙星、罗红霉素、阿莫西林、头孢呋辛或多索茶碱种的任一一种。
5.根据权利要求1所述的一种防治慢性支气管炎的中药组合物,其特征在于,所述中药组合物可根据需要加入可接受的载体制备成任何药用剂型,其中,药学上可接受的载体包括但不限于:甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、红糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁。
6.根据权利要求1-5任一项所述的中药组合物,所述中药组合物的剂型包括颗粒、胶囊、片剂、口服液、合剂或糖浆剂中的任一一种。
7.根据权利要求1-5任一项所述中药组合物的制备方法,其特征在于,该方法为:
步骤1:取小麦25-35份,将小麦加水煎煮后滤过,煎煮液备用;
步骤2:取厚朴10-20份、麻黄8-16份、燀苦杏仁8-16份、清半夏8-16份、干姜3-9份、细辛3-9份、五味子5-10份、石膏15-25份,放置于上述煎煮液内浸泡并煎煮;
步骤3:将步骤2中浸泡并煎煮后的原料用纱布滤过,并干燥成干膏粉,即制得防治慢性支气管炎的中药组合物。
8.根据权利要求7所述中药组合物的制备方法,其特征在于:所述步骤1包括有:取小麦30份,以小麦重量份为基准,剩余原料按原料药的重量份配比,随后先加75-80倍体积份水煎煮小麦,沸前用武火,沸后改用文火保持微沸状态煎煮20-30分钟,捞出小麦,煎煮液备用。
9.根据权利要求7所述中药组合物的制备方法,其特征在于:所述步骤2包括有:用步骤1中煎煮液浸泡剩余原料25-35分钟后煎煮,沸前用武火,沸后改用文火保持微沸状态煎煮110-130分钟。
10.根据权利要求7所述中药组合物的制备方法,其特征在于:所述步骤3中的纱布为单层或双层纱布,且所述纱布的孔径为100-300目。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210903133.4A CN115040629A (zh) | 2022-07-29 | 2022-07-29 | 一种防治慢性支气管炎的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210903133.4A CN115040629A (zh) | 2022-07-29 | 2022-07-29 | 一种防治慢性支气管炎的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115040629A true CN115040629A (zh) | 2022-09-13 |
Family
ID=83166910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210903133.4A Pending CN115040629A (zh) | 2022-07-29 | 2022-07-29 | 一种防治慢性支气管炎的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115040629A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1939527A (zh) * | 2006-10-23 | 2007-04-04 | 胡燕珩 | 治疗呼吸疾病药物 |
CN112007096A (zh) * | 2020-10-16 | 2020-12-01 | 江苏康缘药业股份有限公司 | 一种中药组合物在制备治疗或预防慢性阻塞性肺炎药物中的应用 |
-
2022
- 2022-07-29 CN CN202210903133.4A patent/CN115040629A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1939527A (zh) * | 2006-10-23 | 2007-04-04 | 胡燕珩 | 治疗呼吸疾病药物 |
CN112007096A (zh) * | 2020-10-16 | 2020-12-01 | 江苏康缘药业股份有限公司 | 一种中药组合物在制备治疗或预防慢性阻塞性肺炎药物中的应用 |
Non-Patent Citations (1)
Title |
---|
陈潮祖: "厚朴麻黄汤(《中医治法与方剂》)", pages 1, Retrieved from the Internet <URL:https://mp.weixin.qq.com/s?__biz=MzU0Mjg5MTQyMA==&mid=2247490822&idx=2&sn=c4364ec88314f6ffdcd3de07a93f2988&chksm=fb1291f5cc6518e38b0ef68347c2c4e04aadf7039f3f53c5c68bf127f27e5a1b2072041f3c81&scene=27> * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2520745C2 (ru) | Лекарственная композиция для лечения бронхита и способ ее получения | |
RU2519643C2 (ru) | Фармацевтическая композиция, содержащая ephedrae herba, для лечения бронхита, и способ ее получения | |
US10105408B2 (en) | Traditional Chinese medicine composition and preparation method and use thereof | |
CN101322761B (zh) | 一种治疗气管炎、支气管炎的药物及其制备方法 | |
CN104324125B (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法 | |
CN105079227A (zh) | 一种中药组合物在制备治疗放射性肺损伤药物中的应用 | |
CN115040629A (zh) | 一种防治慢性支气管炎的中药组合物及其制备方法 | |
CN103142870A (zh) | 含有淡竹叶的药物组合物 | |
CN112076247B (zh) | 紫苏叶提取物在制备治疗慢性阻塞性肺疾病药物中的应用 | |
CN104825624A (zh) | 一种中药组合物在制备治疗疱疹性口腔炎的药物中的应用 | |
CN113876844B (zh) | 一种用于治疗慢性气管炎的纯中药藏药及其制备方法和应用 | |
CN108339046A (zh) | 一种治疗咳嗽的中药组合物 | |
CN112891482B (zh) | 一种治疗新型冠状病毒感染的组合物 | |
CN114470110B (zh) | 一种有止痛作用的抗鼻炎中药组合物 | |
WO2015172614A1 (zh) | 五味子总木脂素在制备用于治疗咳嗽的药物或保健品中的应用 | |
WO2008095429A1 (fr) | Glycoprotéine destinée au traitement de maladies pulmonaires obstructives chroniques | |
CN107913331A (zh) | 一种治疗急性会厌炎的中西药复方制剂及制备方法 | |
CN105853749A (zh) | 一种用于治疗慢性肺炎的中药制剂及制备方法 | |
CN112791118A (zh) | 一种预防和/或治疗支气管炎的中药提取物 | |
CN104825623A (zh) | 一种中药组合物在制备治疗急性鼻咽炎的药物中的应用 | |
CN108245636A (zh) | 一种中药僵蝉止咳颗粒及其制备方法 | |
CN117838759A (zh) | 治疗溃疡性结肠炎的连翘叶有效部位及其制备方法和应用 | |
CN117138015A (zh) | 一种预防和治疗过敏性鼻炎的中药组合物 | |
CN116747263A (zh) | 一种治疗复发性口腔溃疡的中药组合物、中药制剂及其制备方法 | |
CN103142827A (zh) | 中药镇咳制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220913 |